SCSven Magnus Carlsen

Sven Magnus Carlsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sven Magnus Carlsen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence and case fatality of aneurysmal subarachnoid hemorrhage admitted to hospital between 2008 and 2014 in Norway

    by Lise R. Øie, Ole Solheim, Paulina Majewska, Trond Nordseth, Tomm B. Müller, Sven M. Carlsen, Heidi Jensberg, Øyvind Salvesen, Sasha Gulati

    Background: To provide age- and sex-specific incidence and case fatality rates for non-traumatic aneurysmal subarachnoid hemorrhage (aSAH) in Norway. We also studied time trends in incidence and case fatality, as well as predictors of death following aSAH. Methods: A nationwide study using discharge data for patients admitted with aSAH between 2008 and 2014. Results: A total of 1732 patients with aSAH were included. The mean age was 60 years (SD 14) and 63% were females. Crude annual incidence was 5.7 per 100,000 person-years (95% CI 5.4–6.0) and was higher in females (6.3 per 100,000, 95% CI 5.9–6.7) compared with males (4.9 per 100,000, 95% CI 4.5–5.3). The annual decline in aSAH incidence was 3.2% per year (p = 0.007). The cumulative proportions of fatalities at days 30, 90, and 1 year were 22%, 25%, and 37%, respectively. The 30-day mortality rate did not change during the study period. Age (HR 0.7–2.2) and aneurysms in the posterior circulation (HR 1.7, 95% CI 1.3–2.3, p = 0.001) were associated with higher 30-day case fatality following aSAH, while aneurysm repair (HR 0.2, 95% CI 0.2–0.3, p < 0.001) was associated with lower risk. Conclusions: The incidence of aSAH declined in Norway between 2008 and 2014. Case fatality following aSAH continues to be high, and the 30-day mortality during the study period was unchanged. Increasing age and aneurysms in the posterior circulation were associated with increased risk of death within 30 days following aSAH.


  • Open Access

    Surgery for herniated lumbar disc in private vs public hospitals: A pragmatic comparative effectiveness study

    by Mattis A. Madsbu, Øyvind Salvesen, Sven M. Carlsen, Steinar Westin, Kristian Onarheim, Øystein P. Nygaard, Tore K. Solberg, Sasha Gulati

    Background: There is limited evidence on the comparative performance of private and public healthcare. Our aim was to compare outcomes following surgery for lumbar disc herniation (LDH) in private versus public hospitals. Methods: Data were obtained from the Norwegian registry for spine surgery. Primary outcome was change in Oswestry disability index (ODI) 1 year after surgery. Secondary endpoints were quality of life (EuroQol EQ-5D), back and leg pain, complications, and duration of surgery and hospital stays. Results: Among 5221 patients, 1728 in the private group and 3493 in the public group, 3624 (69.4%) completed 1-year follow-up. In the private group, mean improvement in ODI was 28.8 points vs 32.3 points in the public group (mean difference − 3.5, 95% CI − 5.0 to − 1.9; P for equivalence < 0.001). Equivalence was confirmed in a propensity-matched cohort and following mixed linear model analyses. There were differences in mean change between the groups for EQ-5D (mean difference − 0.05, 95% CI − 0.08 to − 0.02; P = 0.002) and back pain (mean difference − 0.2, 95% CI − 0.2, − 0.4 to − 0.004; P = 0.046), but after propensity matching, the groups did not differ. No difference was found between the two groups for leg pain. Complication rates was lower in the private group (4.5% vs 7.2%; P < 0.001), but after propensity matching, there was no difference. Patients operated in private clinics had shorter duration of surgery (48.4 vs 61.8 min) and hospital stay (0.7 vs 2.2 days). Conclusion: At 1 year, the effectiveness of surgery for LDH was equivalent in private and public hospitals.


  • Open Access

    Differences Between Flash Glucose Monitor and Fingerprick Measurements

    by Odd Martin Staal, Heidi Marie Umbach Hansen, Sverre Christian Christiansen, Anders Lyngvi Fougner, Sven Magnus Carlsen, Øyvind Stavdahl

    Freestyle Libre (FL) is a factory calibrated Flash Glucose Monitor (FGM). We investigated Mean Absolute Relative Difference (MARD) between Self Monitoring of Blood Glucose (SMBG) and FL measurements in the first day of sensor wear in 39 subjects with Type 1 diabetes. The overall MARD was 12.3%, while the individual MARDs ranged from 4% to 25%. Five participants had a MARD ≥ 20%. We estimated bias and lag between the FL and SMBG measurements. The estimated biases range from −1.8 mmol / L to 1.4 mmol / L , and lags range from 2 min to 24 min . Bias is identified as a main cause of poor individual MARDs. The biases seem to persist in days 2–7 of sensor usage. All cases of MARD ≥ 20% in the first day are eliminated by bias correction, and overall MARD is reduced from 12.3% to 9.2%, indicating that adding support for voluntary user-supplied bias correction in the FL could improve its performance.


  • Open Access

    Hemoglobin A1c as screening for gestational diabetes mellitus in Nordic Caucasian women

    by Ingrid Hov Odsæter, Arne Åsberg, Eszter Vanky, Siv Mørkved, Signe Nilssen Stafne, Kjell Åsmund Salvesen, Sven Magnus Carlsen

    Gestational diabetes mellitus (GDM) increases the risk for preeclampsia and macrosomia. GDM is conventionally diagnosed by an oral glucose tolerance test (OGTT). Hemoglobin A1c (HbA1c) is a marker for the average glucose level the last 2–3 months. We aimed to study if HbA1c alone or in combination with patient characteristics can be used to screen for GDM and reduce the number of OGTTs, and whether it could predict preeclampsia or birth weight. 855 women from a previous study on the effect of exercise on GDM prevalence were eligible, whereof 677 were included. GDM was diagnosed by WHO 1999 criteria (GDM-WHO) and modified IADPSG criteria (GDM-IADPSG), at pregnancy weeks 18–22 and 32–36. HbA1c analyzed at pregnancy weeks 18–22 and 32–36, variables from patient history and clinical examination were considered for logistic regression models. The diagnostic accuracy was assessed by ROC curve analysis. Accumulated GDM prevalence was 6.7 % by WHO and 7.2 % by modified IADPSG criteria. Nearly a third could potentially have avoided an OGTT by using HbA1c to exclude GDM-IADPSG with a sensitivity of 88 % at week 18–22 and 97 % at week 32–36. Further, 16 % could have avoided an OGTT with a sensitivity of 96 % using HbA1c at week 18–22 to exclude GDM-IADPSG throughout pregnancy. HbA1c was not accurate at diagnosing GDM-IADPSG, and it was inaccurate at screening for GDM-WHO at any time point. Adding other predictors did not increase the number of potentially avoidable OGTTs significantly. HbA1c was not significantly associated with preeclampsia or birth weight. HbA1c could potentially reduce the number of OGTTs.


  • Open Access

    HbA1c as screening for gestational diabetes mellitus in women with polycystic ovary syndrome

    by Ingrid Hov Odsæter, Arne Åsberg, Eszter Vanky, Sven Magnus Carlsen

    Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes such as preeclampsia and macrosomia. Women with polycystic ovary syndrome (PCOS) are at increased risk of developing GDM. Today, GDM is diagnosed by oral glucose tolerance test (OGTT), a rather cumbersome test for the women and health care system. The objectives of this study were to investigate whether HbA1c in first trimester of pregnancy could be used as a screening test for GDM in first trimester and throughout pregnancy in order to reduce the number of OGTTs, and whether it could predict preeclampsia and macrosomia in women with PCOS. Post hoc analyses of data from 228 women from a prospective, randomised, multicenter study comparing metformin to placebo from first trimester to delivery. Fasting and 2-h plasma glucose were measured during a 75 g OGTT in first trimester, gestational week 19 and 32 as well as fasting plasma glucose in gestational week 36. GDM was diagnosed by WHO criteria from 1999 in first trimester and throughout pregnancy and by modified IADPSG criteria (i.e. lacking the 1-h plasma glucose value) in first trimester. The diagnostic accuracy was assessed by logistic regression and ROC curve analysis. The area under the ROC curve for first trimester HbA1c for screening of GDM diagnosed by WHO criteria in first trimester was 0.60 (95 % CI 0.44-0.75) and 0.56 (95 % CI 0.47-0.65) for GDM diagnosed throughout pregnancy. Only 2.2 % (95 % CI 0.7-5.1 %) of the participants could have avoided OGTT. HbA1c was not statistically significantly associated with GDM diagnosed by modified IADPSG criteria in first trimester. However, first trimester HbA1c was statistically significantly associated with preeclampsia. Both HbA1c and GDM by WHO criteria in first trimester, but not by IADPSG, were negatively associated with birth weight. First trimester HbA1c can not be used to exclude or predict GDM in women with PCOS, but it might be better to predict preeclampsia than the GDM diagnosis.


  • Androgen levels are associated with blood pressure in pregnant women after term

    by Sven M. Carlsen, Runa Heimstad

    Objective. To assess possible associations between androgen, estrogen and insulin levels and blood pressure in pregnant women after term, compared with the effect of other well‐known factors. Design. Cross‐sectional retrospective study. Setting. University Hospital, Trondheim region. Population. Four hundred and eighty‐nine post‐term women with uncomplicated pregnancies. Methods. Blood pressure measurements and fasting serum samples drawn one week beyond the estimated day of delivery (defined as 41+2weeks). Main Outcome Measures. Blood pressure, maternal age, body mass index, parity, smoking habits and serum levels of dehydroepiandrosterone sulfate, androstendione, free testosterone index, estradiol, estriol, progesterone, 17‐hydroxy‐progesterone and insulin. Results. In univariate linear regression analyses, body mass index, androstendione, free testosterone index and insulin were positively associated and parity was negatively associated with both systolic and diastolic blood pressure. In multivariate linear regression analyses, systolic blood pressure was positively associated with body mass index and free testosterone index, but negatively associated with parity and 17‐hydroxy‐progesterone levels, while diastolic blood pressure was positively associated with age and free testosterone index, but negatively associated with parity and 17‐hydroxy‐progesterone levels. Conclusion. Testosterone may increase blood pressure in pregnant women, while 17‐hydroxy‐progesterone may have the opposite effect.


  • Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure

    by Sven M. Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Øivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L. Fougner, Jens Bollerslev, on behalf of the POTA study group

    Objective Treatment with somatostatin analogues is the primary medical treatment of acromegaly. Controversies still exist whether acute octreotide effect predicts long‐term biochemical effects, tumour regression or surgical cure. This prospective study investigates effect of 6‐month treatment with octreotide long‐acting repeatable (LAR) on insulin‐like growth factor‐1 (IGF‐1) and growth hormone (GH) levels, pituitary function, tumour regression and postoperative cure in de novo acromegalic patients. Design and methods After a baseline evaluation including fasting hormone levels, MRI scan and an acute 50 μg octreotide test, 32 patients were treated with octreotide LAR 20 mg every 28th day for 6 months before surgery. Treatment effects on IGF‐1 and GH levels, serum hormone levels and tumour volume were monitored. Surgical cure was evaluated 3 months postoperatively. Results Mean tumour volume reduction was 35%, in one‐third of the patients more than 50%, while approximately one‐third achieved biochemical remission evaluated by normalized IGF‐1 levels. The GH reduction following an acute octreotide test was 81 ± 19% and associated with long‐term GH reduction (r = 0·78, P < 0·0005). However, neither acute (r = 0·29, P = 0·12) nor the long‐term octreotide effect (r = 0·11, P = 0·58) on GH levels was associated with tumour volume reduction and did not predict subsequent surgical cure. Conclusion Six months of long‐acting octreotide using a fixed dose, 1/3 of the patients came in biochemical remission, while 2/3 had significant tumour reduction. Moreover, an acute effect of octreotide seemed to be a prerequisite for long‐term effect.


  • Metformin Versus Placebo from First Trimester to Delivery in Polycystic Ovary Syndrome: A Randomized, Controlled Multicenter Study

    by Eszter Vanky, Solhild Stridsklev, Runa Heimstad, Pål Romundstad, Kristin Skogøy, Odrun Kleggetveit, Sissel Hjelle, Philip von Brandis, Torunn Eikeland, Karin Flo, et al.

  • Open Access

    Mid‐pregnancy androgen levels associated with breastfeeding

    by Sven Carlsen, Geir Jacobsen, Eszter Vanky

    Click on the article title to read more.


  • Open Access

    Mid‐pregnancy androgen levels are negatively associated with breastfeeding

    by Sven Magnus Carlsen, Geir Jacobsen, Eszter Vanky

    Objective. Breastfeeding depends on endocrine changes during pregnancy. The association between gestational hormones and lactation has been sparsely investigated. Previously, androgens were used for lactation inhibition. We investigated a possible association between second trimester maternal androgen levels and breastfeeding. Design. Prospective observational study.Setting. University hospital setting. Population. Women from a random sample of pregnancies (n = 63) and from a group with an increased risk for giving birth to a small‐for‐gestational age newborn (n = 118) were included. All participants had singleton pregnancies and one or two previous births. Methods. Maternal androgen levels were measured in gestational week 25. The association with reported breastfeeding was explored by univariate and multivariate linear regression analyses. Analyses were adjusted for factors known to be associated with breastfeeding. Main outcome measures. Breastfeeding at six weeks, three months, and six months postpartum. Results. In the random group, breastfeeding at three and six months was negatively associated with maternal testosterone, androstendione, and free testosterone index levels. After correction for maternal age, education and smoking, breastfeeding at both three and six months was negatively associated with the free testosterone index. In the group of women with an increased risk for giving birth to a small‐for‐gestational age newborn, breastfeeding at six weeks and three months was associated negatively with maternal dehydroepiandrosterone and this association persisted after correction for maternal age, education, and smoking. Conclusions. Maternal androgen levels in mid‐pregnancy are negatively associated with breastfeeding.